Autocrine CXCL12 has similar pre-clinical effects in lung cancer progression [28] andhas been correlated with positive clinical outcomes in patients with osteosarcoma or breast cancers [31], [34]. This evidence concerns the gene CXCL12 and breast carcinoma.